Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb Company (BMY)
:BMY
Holding BMY?
Track your performance easily
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.35 - $61.08
Previous CloseN/A
Volume3.98M
Average Volume (3M)10.58M
Market Cap
$113.05B
Enterprise Value$148.45B
Total Cash (Recent Filing)$6.35B
Total Debt (Recent Filing)$5.72B
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Feb 06, 2025EPS Estimate
1.47Last Dividend Ex-Date
Jan 03, 2025Dividend Yield4.3%
Share Statistics
EPS (TTM)-3.60
Shares Outstanding2,028,176,600
10 Day Avg. Volume9,251,201
30 Day Avg. Volume10,582,199
Standard Deviation0.06
R-Squared0.14
Alpha-0.00233
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.39
Price to Cash Flow (P/CF)5.10
P/FCF Ratio5.40
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue3.13
Enterprise Value/Gross Profit4.33
Enterprise Value/Ebitda32.65
Forecast
1Y Price Target
$61.80Price Target Upside9.61% Upside
Rating ConsensusHold
Number of Analyst Covering16
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Financial Performance And Market PotentialCobenfy is projected to become a $10 billion-plus drug, with confidence in its launch for schizophrenia and potential in Alzheimer's psychosis and Bipolar 1 disorder.
Product Launch And AdoptionThe initial launch of Cobenfy is progressing well, with patients receiving an initial 30-day free sample.
Regulatory Approval And Market AccessCobenfy's favorable benefit/risk profile compared to currently available treatments has been highlighted.
Bears Say
Financial PerformanceThe company will face meaningful revenue and margin compression in the '26-'30 period, which does not appear to be reflected at current valuation.
Patent ExpirationsBristol-Myers Squibb Company is facing significant challenges due to ongoing and imminent patent expirations for key products like Revlimid, Eliquis, and Opdivo.
Product Launch ChallengesNewer immunology brands Sotyktu and Zeposia continue to struggle due to challenging access dynamics.
---
Ownership Overview
0.07% Insiders
21.55% Mutual Funds
0.50% Other Institutional Investors
54.70% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb Company’s price range in the past 12 months?
Bristol-Myers Squibb Company lowest stock price was $39.35 and its highest was $61.08 in the past 12 months.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company’s market cap is $113.05B.
When is Bristol-Myers Squibb Company’s upcoming earnings report date?
Bristol-Myers Squibb Company’s upcoming earnings report date is Feb 06, 2025 which is in 19 days.
How were Bristol-Myers Squibb Company’s earnings last quarter?
Bristol-Myers Squibb Company released its earnings results on Oct 31, 2024. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.494 by $0.306.
Is Bristol-Myers Squibb Company overvalued?
According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Undervalued.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company pays a Quarterly dividend of $2.42 which represents an annual dividend yield of 4.3%. See more information on Bristol-Myers Squibb Company dividends here
What is Bristol-Myers Squibb Company’s EPS estimate?
Bristol-Myers Squibb Company’s EPS estimate is 1.47.
How many shares outstanding does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has 2,028,176,600 shares outstanding.
What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?
Bristol-Myers Squibb Company reported an EPS of $1.8 in its last earnings report, beating expectations of $1.494. Following the earnings report the stock price went up 5.914%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?
Among the largest hedge funds holding Bristol-Myers Squibb Company’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb Company’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$61.80 (9.61% Upside)
$61.80 (9.61% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 385.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.39%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
2.64%
Trailing 12-Months
Company Description
Bristol-Myers Squibb Company
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BMY Company Deck
---
BMY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook, with strong performance from the growth portfolio, significant advancements in the pipeline, and successful approval and launch of new products like Cobinfi. However, challenges remain in achieving broader access for certain products and managing inventory impacts. The company's financial discipline and raised guidance further support a positive sentiment.Read More>---
BMY Revenue Breakdown
70.11% U.S.
28.33% International
1.55% Other
---
BMY Stock 12 Month Forecast
Average Price Target
$61.80
▲(9.61% Upside)
Technical Analysis
Merck & Company
―
Pfizer
―
Johnson & Johnson
―
Eli Lilly & Co
―
GlaxoSmithKline
―
Novartis
―
Best Analysts Covering BMY
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+5.27%
reiterated a sell rating 2 months ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +5.27% per trade.
---